Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Study sponsor: OPKO Health, Inc. · OPK
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-06-19Actual
Enrollment · participants2Actual
Source updated2025-07-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.